Research programme: T-cell receptor immunotherapies - bluebird bio/MedigeneAlternative Names: TCR immunotherapies - bluebird bio/Medigene
Latest Information Update: 04 Oct 2016
At a glance
- Originator MediGene AG
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer